1. Search Result
Search Result
Results for "

Nicotine

" in MedChemExpress (MCE) Product Catalog:

355

Inhibitors & Agonists

1

Screening Libraries

7

Biochemical Assay Reagents

17

Peptides

77

Natural
Products

34

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N8723

    Others Neurological Disease
    (1′S,2′S)-Nicotine-1'-oxide is an alkaloid N-oxide from the leaves, stems and roots of Nicotiana tabacum .
    (1′S,2′S)-Nicotine-1'-oxide
  • HY-W004515

    Endogenous Metabolite Others
    3-Pyridineacetic acid hydrochloride is a higher homologue of nicotinic acid, a breakdown product of nicotine (and other tobacco alkaloids) .
    3-Pyridylacetic acid hydrochloride
  • HY-W015806

    Endogenous Metabolite Others
    3-Pyridineacetic acid is a higher homologue of nicotinic acid, a breakdown product of nicotine (and other tobacco alkaloids) .
    3-Pyridineacetic acid
  • HY-G0020S1

    Nicotine N-glucuronide-d3

    Isotope-Labeled Compounds Others
    Nicotine N-β-D-glucuronide-d3 (Nicotine N-glucuronide-d3) is a deuterium labeled compound.
    Nicotine N-β-D-glucuronide-d3
  • HY-W653822

    (2S)-Nicotine 1-N-oxide

    Drug Metabolite Others
    (2'S)-Nicotine 1-oxide ((2S)-Nicotine 1-N-oxide) is an alkaloid N-oxide, which is found in leaves, stems and roots of Nicotiana tabacum .
    (2'S)-Nicotine 1-oxide
  • HY-143997S

    Drug Metabolite Isotope-Labeled Compounds Others
    (Rac)-Nicotine EP impurity A-d4 (hydrochloride) is the deuterium labeled (Rac)-Nicotine EP impurity A hydrochloride[1].
    (Rac)-Nicotine EP impurity A-d4 hydrochloride
  • HY-155452

    Biochemical Assay Reagents Inflammation/Immunology
    SG62 is an amine nicotine haptenand can be used for the study of nicotine dependence .
    SG62
  • HY-N8723S

    Isotope-Labeled Compounds Others
    (1′S,2′S)-Nicotine-1'-oxide-d3 is deuterium labeled (1′S,2′S)-Nicotine-1'-oxide.
    (1′S,2′S)-Nicotine-1'-oxide-d3
  • HY-N10497

    nAChR Neurological Disease
    Dihydro-β-erythroidine is a a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced .
    Dihydro-β-erythroidine
  • HY-W004515R

    Endogenous Metabolite Others
    3-Pyridylacetic acid (hydrochloride) (Standard) is the analytical standard of 3-Pyridylacetic acid (hydrochloride). This product is intended for research and analytical applications. 3-Pyridineacetic acid hydrochloride is a higher homologue of nicotinic acid, a breakdown product of nicotine (and other tobacco alkaloids) .
    3-Pyridylacetic acid hydrochloride (Standard)
  • HY-101347

    nAChR Neurological Disease
    Chlorisondamine (diiodide) is a potent nicotinic acetylcholine receptor (nAChR) antagonist and a ganglion blocker. Chlorisondamine antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way .
    Chlorisondamine diiodide
  • HY-128700A

    Endogenous Metabolite Metabolic Disease
    Nicotinic acid mononucleotide triethylamine is formed from nicotinic acid (NA) via the nicotinic acid phosphoribosyltransferase in the biosynthesis of NAD +. Nicotinate mononucleotide triethylamine is a substrate for nicotinamide mononucleotide/Nicotinic acid mononucleotide adenylyltransferase .
    Nicotinic acid mononucleotide triethylamine
  • HY-155448

    Biochemical Assay Reagents Neurological Disease
    GK56 is a carboxyl nicotine hapten, which contains a linker attached to the 6-position of nicotine. GK56 conjugates to KLH via carbodiimide-mediated reactions .
    GK56
  • HY-155456

    Cytochrome P450 Metabolic Disease
    CD-6 is a flavonoid CYP2A6 inhibitor (IC50: 1.566 μM). CYP2A6 inhibits the metabolism of nicotine to cotinine, resulting in an increase in the amount of nicotine available in the blood, leading to increased smoking behavior. CD-6 mediates CYP2A6 inhibition and can be used in research on smoking cessation or smoking-related diseases .
    CYP2A6-IN-1
  • HY-106559

    GCGR Cardiovascular Disease
    Sorbinicate, a derivative of nicotinic acid, exerts a favourable influence on blood rheology and platelet function .
    Sorbinicate
  • HY-15543A
    CP-809101 hydrochloride
    1 Publications Verification

    5-HT Receptor Neurological Disease
    CP-809101 hydrochloride is a potent and highly selective 5-HT2C receptor agonist, with pEC50s of 9.96, 7.19 and 6.81 M for human 5HT2C, 5HT2B and 5HT2A receptor. CP-809101 hydrochloride inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 hydrochloride also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence .
    CP-809101 hydrochloride
  • HY-15543

    5-HT Receptor Neurological Disease
    CP-809101 is a potent and highly selective 5-HT2C receptor agonist, with pEC50s of 9.96, 7.19 and 6.81 M for human 5HT2C, 5HT2B and 5HT2A receptor. CP-809101 inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence .
    CP-809101
  • HY-107668A

    nAChR Neurological Disease
    TC-1698 is a selective α7 nicotinic acetylcholine receptors agonist with EC50 value of 0.16 μM and 0.46 μM for monkey α7 nicotinic receptor and human α7 nicotinic receptor, respectively. TC-1698 improves memory and has neuroprotective effects. TC-1698 can be used for Alzheimer's disease research .
    TC-1698
  • HY-107668

    nAChR Neurological Disease
    TC-1698 dihydrochloride is a selective α7 nicotinic acetylcholine receptors agonist with EC50 value of 0.16 μM and 0.46 μM for monkey α7 nicotinic receptor and human α7 nicotinic receptor, respectively. TC-1698 dihydrochloride improves memory and has neuroprotective effects. TC-1698 dihydrochloride can be used for Alzheimer's disease research .
    TC-1698 dihydrochloride
  • HY-W002112

    NorNicotine

    Endogenous Metabolite Drug Metabolite Neurological Disease
    (±)-Nornicotine is the primary metabolite of nicotine that is formed through demethylation of nicotine in the genus Nicotiana tabacum L. (±)-Nornicotine is a precursor of tobacco-specific nitrosamine N-nitrosonornicotine. (±)-Nornicotine has detrimental effects to human health .
    (±)-Nornicotine
  • HY-B1304A
    (+)-Sparteine sulfate pentahydrate
    1 Publications Verification

    (+)-Lupinidine sulfate pentahydrate

    nAChR Neurological Disease
    (+)-sparteine (sulfate pentahydrate) is a ganglionic blocking agent. (+)-Sparteine competitively blocks nicotinic ACh receptor in the neurons .
    (+)-Sparteine sulfate pentahydrate
  • HY-P4201

    Vasopressin Receptor Cardiovascular Disease
    JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking .
    JKC 301
  • HY-160251

    (3'R,5k'S)-trans-3'-Hydroxycotinine glucuronide

    Drug Metabolite Others
    3-HC-Gluc ((3’R,5k’s)-trans-3’ -Hydroxycotinine glucuronide) The trans-structure of 3-HC, the main metabolite of nicotine .
    3-HC-Gluc
  • HY-107669

    nAChR Neurological Disease
    nAChR-IN-1 (hydrochloride) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research .
    nAChR-IN-1 hydrochloride
  • HY-B1552B

    nAChR Neurological Disease
    Benzoquinonium dibromide is a nicotinic acetylcholine receptors (nAChRs) antagonist, with an IC50 of 0.46 μM. Benzoquinonium dibromide can block neuromuscular and ganglionic transmission .
    Benzoquinonium dibromide
  • HY-135783
    AT 1001
    1 Publications Verification

    nAChR Neurological Disease
    AT 1001 is a high-affinity and selective antagonist of the α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) (Ki=2.64 nM). AT 1001 reversibly blocks inward currents induced by Epibatidine (HY-101078) in HEK cells transfected with α3β4 nAChR. AT-1001 dose-dependently inhibits nicotine self-administration behavior in rats without affecting food-reinforced responding. AT 1001 can be utilized in the research of nicotine addiction and smoking cessation therapies .
    AT 1001
  • HY-10019

    CP 526555

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline
  • HY-10020

    CP 526555 hydrochloride

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline Hydrochloride
  • HY-10019A

    CP 526555 dihydrochloride

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline dihydrochloride
  • HY-10021

    CP 526555-18

    nAChR ERK p38 MAPK Others Neurological Disease Cancer
    Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline Tartrate
  • HY-147428

    MM-110; (±)​-18-Methoxycoronaridine

    nAChR Parasite Infection Neurological Disease
    Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .
    Zolunicant
  • HY-W002112R

    Endogenous Metabolite Drug Metabolite Neurological Disease
    (±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine. This product is intended for research and analytical applications. (±)-Nornicotine is the primary metabolite of nicotine that is formed through demethylation of nicotine in the genus Nicotiana tabacum L. (±)-Nornicotine is a precursor of tobacco-specific nitrosamine N-nitrosonornicotine. (±)-Nornicotine has detrimental effects to human health .
    (±)-Nornicotine (Standard)
  • HY-154924

    S-NADP

    Calcium Channel Cardiovascular Disease
    Thio-NADP (S-NADP) is a nicotinic acid adenine dinucleotide phosphate (NAADP) inhibitor. Thio-NADP activates partial Ca 2+ release .
    Thio-NADP
  • HY-W082430

    Cytochrome P450 Neurological Disease
    CYP2A6-IN-2 (compound 5) is a CYP2A6 inhibitor. CYP2A6-IN-2 can be used in the study of nicotine dependence .
    CYP2A6-IN-2
  • HY-W001909

    nAChR Metabolic Disease
    Myosmine, a specific tobacco alkaloid in nuts and nut products, has low affinity for a4b2 nicotinic acetylcholinergic receptors (nAChR) with a Ki of 3300 nM .
    Myosmine
  • HY-151129

    nAChR Neurological Disease
    nAChR-IN-1 (2,2,6,6-Tetramethylpiperidin-4-yl heptanoate) is a tetramethylpiperidine heptanoate, a selective nicotinic acetylcholine receptor (nAChR) inhibitor that inhibits nAChRs lacking α5, α6, or β3 subunits. nAChR-IN-1 has the effect of preventing nerve disorder, can be used for nicotinic acetylcholine receptor dysfunction or neurological disorders research .
    nAChR-IN-1
  • HY-10021R

    nAChR ERK p38 MAPK Others Neurological Disease
    Varenicline (Tartrate) (Standard) is the analytical standard of Varenicline (Tartrate). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline (Tartrate) (Standard)
  • HY-10019R

    CP 526555 (Standard)

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (Standard) is the analytical standard of Varenicline. This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
    Varenicline (Standard)
  • HY-10019AR

    CP 526555 dihydrochloride (Standard)

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (dihydrochloride) (Standard) is the analytical standard of Varenicline (dihydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
    Varenicline dihydrochloride (Standard)
  • HY-10020R

    CP 526555 hydrochloride (Standard)

    nAChR Neurological Disease Inflammation/Immunology Cancer
    Varenicline (Hydrochloride) (Standard) is the analytical standard of Varenicline (Hydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].
    Varenicline Hydrochloride (Standard)
  • HY-128068

    Dihydroorotate Dehydrogenase Cancer
    DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC50=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .
    DHODH-IN-17
  • HY-136146

    nAChR Neurological Disease
    SUVN-911 is a potent, selective, brain penetrated and orally bioavailable neuronal nicotinic acetylcholine α4β2 receptor antagonist, with a Ki of 1.5 nM. SUVN-911 has antidepressant activity .
    SUVN-911
  • HY-10019S1

    CP 526555-15N,13C,d2

    nAChR Isotope-Labeled Compounds Neurological Disease Inflammation/Immunology Cancer
    Varenicline- 15N, 13C,d2 is 15N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .
    Varenicline-15N,13C,d2
  • HY-107682

    nAChR Neurological Disease Inflammation/Immunology
    TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain .
    TQS
  • HY-B1337
    Choline chloride
    3 Publications Verification

    nAChR Endogenous Metabolite Cancer
    Choline chloride is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .
    Choline chloride
  • HY-133027

    Tetradecyl nicotinate

    Biochemical Assay Reagents Cancer
    Myristyl nicotinate (Tetradecyl nicotinate) is an ester proagent and a lipophilic derivative of Nicotinic acid. Myristyl nicotinate is being developed for delivery of Nicotinic acid into the skin for prevention of actinic keratosis and its progression to skin cancer. Myristyl nicotinate shows to stimulate epidermal differentiation in photodamaged skin, increasing skin NAD content and strengthening the skin barrier .
    Myristyl nicotinate
  • HY-111051

    nAChR Neurological Disease
    JN403 is an orally active and selective α7 nicotinic acetylcholine receptor agonist. JN403 can be used in the study of central nervous system disorders .
    JN403
  • HY-P1271

    Catestatin (cattle)

    nAChR Cardiovascular Disease
    Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
    Catestatin
  • HY-B1337B

    nAChR Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Glycerophosphoinositol choline is an essential nutrient that activates alpha7 nicotinic receptors and has analgesic and anti-inflammatory activity. Glycerophosphoinositol choline can affect diseases such as liver disease, atherosclerosis and neurological disorders .
    Glycerophosphoinositol choline
  • HY-P1271A

    nAChR Cardiovascular Disease
    Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure . Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release .
    Catestatin TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: